Wegovy® (semaglutide 2.4mg) is the FDA-approved weekly injection proven to help patients lose 15%+ of body weight. Real prescription, real medication, licensed physician — online in minutes.
Most weight loss treatments try to fight your biology. Wegovy® works with it — using the same hormonal signals your body already depends on to regulate hunger.
When you eat, your gut releases a hormone called GLP-1 (glucagon-like peptide-1). This hormone travels to your brain and signals that you're full — it also slows digestion so your body has more time to absorb nutrients. Semaglutide, the active ingredient in Wegovy®, is a GLP-1 receptor agonist. It mimics this hormone and amplifies the satiety signal far beyond what food alone triggers.
The practical effect: food becomes less interesting. Cravings quiet down. You feel full sooner and stay full longer. Gastric emptying slows, meaning food stays in your stomach longer and your blood sugar rises more gradually after meals. None of this requires willpower — it's biology working in your favor, not against you.
Wegovy® received FDA approval in June 2021, backed by the landmark STEP clinical trial program. In STEP 1 — the largest trial — 1,961 adults with obesity took semaglutide 2.4mg weekly for 68 weeks. The results were remarkable: participants lost an average of 15.3% of their total body weight. That's roughly 34 pounds for a 220-pound person. For context, previous weight loss medications rarely exceeded 5–8% average weight loss in clinical trials.
Wegovy® is manufactured by Novo Nordisk and approved specifically for chronic weight management — not just diabetes. This distinction matters: the approved dose (2.4mg) is higher than Ozempic® (2.0mg), which is why clinical results for weight loss are consistently better with Wegovy®.
Wegovy® is FDA-approved for specific patient profiles. Review the criteria below to see if you may be eligible for a prescription.
Adults with a body mass index of 30 or higher qualify for Wegovy® regardless of other health conditions.
If your BMI is 27–29.9, you may still qualify if you have hypertension, type 2 diabetes, high cholesterol, or sleep apnea.
Wegovy® is approved for adults aged 18 and above. It is also approved for adolescents 12+ in a separate dosing protocol.
Wegovy® should not be used during pregnancy or breastfeeding. Effective contraception is recommended for women of childbearing age during treatment.
Wegovy® carries a boxed warning for medullary thyroid carcinoma (MTC). Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 should not use semaglutide.
Patients who have had a serious allergic reaction (anaphylaxis, angioedema) to semaglutide or any Wegovy® ingredient are not candidates for treatment.
Not sure if you qualify? Our physicians will review your full medical history during your free consultation — no commitment required. Most patients who apply receive a response within 24 hours.
Check My EligibilityFrom first click to first dose, most patients complete the entire process in under a week. Here's exactly what to expect.
Fill out a confidential medical intake form online in about 5 minutes. Our board-certified physicians review your health profile, weight history, current medications, and treatment goals to determine whether Wegovy® is right for you.
If approved, a licensed US physician writes your Wegovy® prescription. We handle prior authorization coordination with your insurance company and answer any coverage questions. Cash-pay options are available if you don't have insurance or prefer to pay out of pocket.
Your Wegovy® auto-injector pens ship directly to your door in discreet packaging. Monthly check-ins with your care team keep your treatment on track, and your physician adjusts your dose as you progress through the escalation schedule.
Wegovy® uses a gradual titration schedule to minimize side effects while building toward the full therapeutic dose. Here's the standard schedule approved by the FDA.
Your treatment begins at the lowest available dose — 0.25mg once weekly. This phase is designed entirely for tolerance building, not active weight loss. Many patients notice modest appetite reduction even at this dose. Some experience mild nausea or digestive changes as their body adjusts to semaglutide for the first time. This is normal and usually resolves within 1–2 weeks.
The dose doubles to 0.5mg weekly. Appetite suppression becomes more noticeable, and many patients begin experiencing a meaningful reduction in food cravings and overall caloric intake. Most patients at this phase begin to lose weight. The dose increase may bring a brief recurrence of mild nausea, which typically subsides within a week.
At 1.0mg, patients often see a meaningful acceleration in weight loss. This is the maintenance dose used in Ozempic® for diabetes — and even at this level, patients in the STEP trials were losing significant weight. Blood sugar markers, blood pressure, and energy levels frequently show improvement at this stage. Your physician monitors your progress and adjusts if needed.
Most patients tolerate the step to 1.7mg well after three prior escalations. Weight loss typically accelerates again at this dose. Feelings of fullness after small portions become more pronounced. Some patients may remain at 1.7mg long-term if they achieve their goals before reaching the full 2.4mg dose.
This is the maximum FDA-approved dose for chronic weight management — the dose that drove the 15.3% average weight loss seen in the STEP 1 trial. Most patients remain at 2.4mg for the duration of their treatment. Your physician will continue monitoring your response, adjusting the plan based on your progress, side effects, and long-term goals.
The STEP clinical trial program, involving over 4,500 patients across multiple studies, represents the most comprehensive evidence base ever assembled for a weight loss medication. Here's what the data shows.
68-week randomized controlled trial, n=1,961 adults with obesity
Beyond the scale: metabolic and quality-of-life improvements observed in clinical trials
We believe you deserve to know what things cost before you commit. Here's exactly what to expect.
A board-certified physician reviews your full medical history, determines your eligibility for Wegovy®, discusses your goals, and coordinates your prescription — at no cost to you.
We work directly with your insurance company to maximize your coverage. Wegovy® is covered by many commercial insurance plans. Prior authorization support included.
Real answers to the questions our patients ask most often about Wegovy® and online prescriptions.
Complete your free consultation in minutes. Licensed physicians available in all 50 states. Get the FDA-approved treatment that's changing weight loss.
Start My Free ConsultationNo commitment·Cancel anytime·HIPAA-secure